Paul Fields

5.1k total citations · 1 hit paper
58 papers, 2.5k citations indexed

About

Paul Fields is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Paul Fields has authored 58 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 17 papers in Immunology. Recurrent topics in Paul Fields's work include Lymphoma Diagnosis and Treatment (27 papers), T-cell and Retrovirus Studies (17 papers) and Vector-Borne Animal Diseases (11 papers). Paul Fields is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), T-cell and Retrovirus Studies (17 papers) and Vector-Borne Animal Diseases (11 papers). Paul Fields collaborates with scholars based in United Kingdom, United States and Canada. Paul Fields's co-authors include N. George Mikhaeel, A.R. Timothy, Michael O’Doherty, Martin Hutchings, Olivier Hermine, Siobhan Crichton, Ali Bazarbachi, Alistair Robson, Alan Dean and Michael C. Cox and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul Fields

57 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

2010 558 citations Paul Fields et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Fields United Kingdom	21	1.2k	807	617	607	386	58	2.5k
Dai Chihara United States	25	1.2k 1.0×	932 1.2×	477 0.8×	119 0.2×	352 0.9×	128	2.1k
John P. Greer United States	31	1.5k 1.2×	1.3k 1.6×	772 1.3×	745 1.2×	379 1.0×	119	3.3k
S. H. Swerdlow United States	2	1.8k 1.5×	1.2k 1.5×	577 0.9×	306 0.5×	413 1.1×	3	3.4k
Jean Gabarre France	31	2.4k 1.9×	2.2k 2.8×	429 0.7×	165 0.3×	751 1.9×	81	3.3k
Mary Jo Lechowicz United States	23	1.4k 1.1×	846 1.0×	746 1.2×	829 1.4×	197 0.5×	122	2.2k
Michèle L. Donato United States	34	784 0.6×	1.3k 1.6×	1.4k 2.4×	239 0.4×	151 0.4×	121	4.4k
Enrico Roggero Switzerland	25	1.8k 1.5×	972 1.2×	245 0.4×	154 0.3×	358 0.9×	48	2.6k
William S. Velasquez United States	29	2.5k 2.0×	1.4k 1.7×	487 0.8×	101 0.2×	638 1.7×	58	3.5k
Réda Bouabdallah France	28	1.9k 1.5×	2.0k 2.5×	577 0.9×	153 0.3×	600 1.6×	101	4.0k
Pak‐Kwan Hui China	25	793 0.6×	722 0.9×	430 0.7×	238 0.4×	132 0.3×	46	1.8k

Countries citing papers authored by Paul Fields

Since Specialization

Citations

This map shows the geographic impact of Paul Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Fields more than expected).

Fields of papers citing papers by Paul Fields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Fields. The network helps show where Paul Fields may publish in the future.

Co-authorship network of co-authors of Paul Fields

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Fields. A scholar is included among the top collaborators of Paul Fields based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Fields. Paul Fields is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Michelle M., Paul Fields, Luca Lonini, et al.. (2023). 163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database. SHILAP Revista de lepidopterología. A182–A184.

Walewska, Renata, Toby A. Eyre, Sally F. Barrington, et al.. (2023). Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. British Journal of Haematology. 204(1). 86–107. 8 indexed citations

Rowan, Aileen, Richard Dillon, Aviva Witkover, et al.. (2020). Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood. 135(23). 2023–2032. 48 indexed citations

Phillips, Adrienne A., Paul Fields, Olivier Hermine, et al.. (2019). Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Repositorio Académico USMP. 5 indexed citations

Eyre, Toby A., Nicolás Martínez‐Calle, Catherine Hildyard, et al.. (2019). Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. Journal of Internal Medicine. 285(6). 681–692. 32 indexed citations

Eyre, Toby A., Amy A. Kirkwood, Julia Wolf, et al.. (2019). Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity. British Journal of Haematology. 187(2). 185–194. 35 indexed citations

Fields, Paul & David Wrench. (2017). Hodgkin lymphoma. Medicine. 45(5). 305–310. 3 indexed citations

Mikhaeel, N. George, Daniel Smith, Joel Dunn, et al.. (2016). Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. European Journal of Nuclear Medicine and Molecular Imaging. 43(7). 1209–1219. 209 indexed citations

Fields, Paul, et al.. (2014). Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma. Retrovirology. 11(S1). 1 indexed citations

10.

Kalsi, Tania, G. Babic-Illman, Paul Fields, et al.. (2014). The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. British Journal of Cancer. 111(12). 2224–2228. 49 indexed citations

11.

Kalsi, Tania, G. Babic-Illman, Simon Hughes, et al.. (2014). 107 * VALIDITY & RELIABILITY OF A COMPREHENSIVE GERIATRIC ASSESSMENT SCREENING QUESTIONNAIRE (CGA-GOLD) IN OLDER PEOPLE WITH CANCER. Age and Ageing. 43(suppl 1). i30–i30. 4 indexed citations

12.

Phillips, Adrienne A., Paul Fields, Olivier Hermine, et al.. (2014). Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).. Journal of Clinical Oncology. 32(15_suppl). TPS8622–TPS8622. 1 indexed citations

13.

Kalsi, Tania, G. Babic-Illman, Paul J. Ross, et al.. (2013). Feasibility, utility of comprehensive geriatric assessment screening via postal questionnaire (CGA-GOLD) in older people with cancer. European Geriatric Medicine. 4. S96–S96. 4 indexed citations

14.

Montoto, Silvia, Kate Shaw, Jessica Okosun, et al.. (2012). HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. Journal of Clinical Oncology. 30(33). 4111–4116. 105 indexed citations

15.

Ceesay, M. Mansour, Estella Matutes, Graham P. Taylor, et al.. (2011). Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leukemia Research. 36(7). 857–861. 16 indexed citations

16.

Fields, Paul, Andrew Webb, Christopher Pocock, et al.. (2011). First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. Blood. 118(21). 1634–1634. 2 indexed citations

17.

Bruch, G., et al.. (2009). Thyroid lymphoma and airway obstruction - is there a rationale for surgical management?. International Journal of Clinical Practice. 63(11). 1647–1652. 8 indexed citations

18.

Mikhaeel, G., et al.. (2005). B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.. Blood. 106(11). 1500–1500. 5 indexed citations

19.

Fields, Paul, G. Mikhaeel, Jeremy L. Freeman, et al.. (2003). Diffuse large B cell lymphoma: Characterisation of immunohistochemical and interim PET scan analysis and correlation with outcome.. Blood. 102(11). 1 indexed citations

20.

Nasser, Shuaib, Paul Fields, D Calver, Barry Bresnihan, & T. Gibson. (1993). IRREVERSIBLE BLINDNESS IN SYSTEMIC LUPUS ERYTHEMATOSIS. Lara D. Veeken. 32(10). 935–936. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact